Allogene Therapeutics ALLO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$42.61M+28.7% | -$38.81M+35.3% | -$41.4M+37.5% | -$50.94M+23.2% | -$59.73M+8.1% | ||
| $2.87M-7.4% | $3.06M-5.4% | $3.1M-3.4% | $3.11M-14.8% | $3.1M-12.8% | ||
| $8.27M-32.1% | $8.13M-36.8% | $8.65M-35.4% | $8.69M-35.9% | $12.18M+2.1% | ||
| $663K+297% | —— | -$1.07M+85.2% | -$422K-106% | -$336K-185% | ||
| -$5.1M+2.3% | -$118K— | —— | —— | -$5.22M+8.2% | ||
| -$84K+80.2% | $102K+115% | —— | $1.93M+385% | -$425K+70.6% | ||
| $316K+92.7% | $329K+246% | $359K+212% | $283K+590% | $164K+1,950% | ||
| -$2.2M-20.1% | -$1.89M-6.4% | -$1.86M-10.0% | -$1.93M-17.7% | -$1.83M-51.6% | ||
| -$12.91M+75.6% | -$27.6M+24.8% | -$29.69M+32.7% | -$39.03M+38.6% | -$52.93M+5.3% | ||
| $9K-90.9% | $0-100% | $243K-43.4% | $44K— | $99K+1,138% | ||
| $101.69M+102% | $28.38M-39.6% | $49.73M-73.9% | $9.92M-76.7% | $50.23M-38.1% | ||
| $72.12M+27.6% | $0— | -$110.3M— | $53.8M-54.1% | $56.5M-45.3% | ||
| -$29.59M-579% | $33.61M-38.8% | $11.94M— | $43.84M-41.3% | $6.18M-72.1% | ||
| $450K-95.5% | —— | $257K-62.2% | —— | $10M— | ||
| $21.12M+51.0% | $7.86M+36.8% | $3.24M+377% | $5.07M-95.3% | $13.99M+748% | ||
| -$21.38M+34.7% | —— | -$14.52M+87.8% | —— | -$32.76M-2.0% | ||
| -$5.1M+2.3% | -$118K— | —— | —— | -$5.22M+8.2% | ||
| -$23.48M-2,805% | $7K— | $0-100% | $1.84M-91.4% | $868K— | ||
| -$2.2M-20.1% | -$1.89M-6.4% | -$1.86M-10.0% | -$1.93M-17.7% | -$1.83M-51.6% | ||
| $316K+92.7% | $329K+246% | $359K+212% | $283K+590% | $164K+1,950% | ||
| -$1.13M-282% | -$986K— | -$1.01M-396% | -$1.87M-200% | $623K+624% | ||
| $885K-32.2% | $821K-50.3% | $923K-45.7% | $1.17M-46.8% | $1.31M-53.3% | ||
| $3.23M+0.2% | $3.24M+1.2% | $3.17M+1.0% | $3.29M+6.0% | $3.23M+5.2% | ||
| $72.12M+27.6% | $61.99M-39.3% | $61.91M-43.6% | $53.8M-54.1% | $56.5M-45.3% | ||
| $0-100% | —— | —— | $3.56M+56.1% | $3.35M— | ||
| $4K— | $0— | $0— | $0-100% | $0-100% | ||
| $450K-29.5% | —— | $257K-62.2% | —— | $638K-25.5% | ||
| $146K— | —— | —— | $215K— | $0— | ||
| -$2.2M-20.1% | -$1.89M-6.4% | -$1.86M-10.0% | -$1.93M-17.7% | -$1.83M-51.6% | ||
| $1.07M-5.4% | $1.05M-6.2% | $1.03M-29.1% | $1.15M-25.5% | $1.13M-2.1% | ||
| -$12.92M+75.6% | -$27.6M+25.3% | -$29.93M+32.8% | -$39.07M+38.6% | -$53.03M+5.1% | ||
| -$12.92M+75.6% | -$27.6M+25.3% | -$29.93M+32.8% | -$39.07M+38.6% | -$53.03M+5.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.